Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.

The Japanese Journal of Radiology, published by SPRINGER, serves as a premier platform for disseminating cutting-edge research and clinical advancements in the fields of radiology, nuclear medicine, and imaging. With an ISSN of 1867-1071 and E-ISSN 1867-108X, this journal has established itself as a vital resource for practitioners, researchers, and students alike. Renowned for its high-quality peer-reviewed articles, it currently enjoys a respectable impact factor within the Q2 category of Scopus rankings, placing it in the 69th percentile among 333 journals in its field. The journal has seen consistent convergence of research from 2009 to 2024, further underscoring its commitment to advancing the understanding of radiological practices. Importantly, the journal offers Open Access options to facilitate widespread dissemination of knowledge, ensuring that vital research reaches its audience without barriers. Addressed in Japan, the Japanese Journal of Radiology plays a critical role in enhancing the global discourse on medical imaging, making it an essential resource for anyone engaged in this dynamic field.

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

Journal of Radiotherapy in Practice is a peer-reviewed journal published by Cambridge University Press, focusing on the evolving field of radiotherapy and its application in clinical practice. With ISSN 1460-3969 and E-ISSN 1467-1131, this journal serves as a critical platform for researchers, clinicians, and students in oncology and radiology, providing vital insights into treatment methodologies, patient care, and innovative practices. Although indexed in Q4 quartiles for both Oncology and Radiology, Nuclear Medicine and Imaging, the journal plays an essential role in disseminating clinical findings and advancing the science of radiotherapy since its inception in 1999. Authors are encouraged to contribute their research, case studies, and reviews that align with the journal's objectives, fostering a collaborative environment for sharing knowledge. Despite its current rankings, the journal aims to enhance its impact and visibility in the scientific community, thereby enriching professional practice and patient outcomes in the realm of radiotherapy.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Brachytherapy, published by ELSEVIER SCIENCE INC, serves as a pivotal journal in the realms of Oncology and Radiology, Nuclear Medicine, and Imaging. With an ISSN of 1538-4721 and an E-ISSN of 1873-1449, the journal disseminates cutting-edge research and advancements from 2002 to 2024, focusing on the innovative field of brachytherapy. Although classified in the Q3 category for Oncology and Q2 for Radiology, Nuclear Medicine, and Imaging based on the 2023 quartile rankings, it continues to make significant contributions to clinical practice and methodology. Brachytherapy holds a respectable position in Scopus, ranking #155/333 and #234/404 in its respective categories, which reflects its importance and relevance to the scientific community. This journal is indispensable for researchers, healthcare professionals, and students looking to stay abreast of the latest techniques and therapeutic approaches in cancer treatment and imaging practices.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.